Additional file 1: Table S3. Transcript levels of domains in children with cerebral malaria (CM) var who had Primers CM CM Pa PfHRP2 levels PfHRP-2-high PfHRP-2-low ≥ (n=62) (n=35) 1700ng/ml (high) CIDRa1.1 13.0 (1-43.3) 10.9 (1-48.3) 0.99 or <1700ng/ml Group B-EPCR 14.8 (3.80-46.2) 16.6 (3.44-58.6) 0.95 (low) binders CIDRa1.4/6a 4.76 (1.35-16.6) 5.08 (1-12.7) 0.45 Group A-EPCR 18.2 (5.24-36.6) 15.4 (7.14-43.9) 0.76 binders 38.6 (17.0-84.6) 58.1 (23.3-102) 0.48 CIDRα1-EPCR binders CIDRd 1.34 (1-4.02) 1 (1-5.57) 0.55 DBLa1ALL 53.8 (20.8-78.0) 36.9 (1-107) 0.62 DBLa1.5/6/8 types 10.8 (5.21-26.6) 11.5 (2.75-22.9) 0.70 n=55 DBLa2/1.1/2/4/7 43.5 (23.6-69.8) 49.1 (28.4-70.2) 0.42 types n=55 a Median transcript levels were compared using Mann-Whitney U test Figure S1. In siico characterization of primers used in the present study Additional file 1:
Additional file 1: Table S3. Transcript levels of var domains in children with cerebral malaria (CM) who had PfHRP2 levels ≥ 1700ng/ml (high) or <1700ng/ml (low) Primers PfHRP-2-high CM (n=62) PfHRP-2-low CM (n=35) Pa CIDRa1.1 13.0 (1-43.3) 10.9 (1-48.3) 0.99 Group B-EPCR binders 14.8 (3.80-46.2) 16.6 (3.44-58.6) 0.95 CIDRa1.4/6a 4.76 (1.35-16.6) 5.08 (1-12.7) 0.45 Group A-EPCR binders 18.2 (5.24-36.6) 15.4 (7.14-43.9) 0.76 CIDRα1-EPCR binders 38.6 (17.0-84.6) 58.1 (23.3-102) 0.48 CIDRd 1.34 (1-4.02) 1 (1-5.57) 0.55 DBLa1ALL 53.8 (20.8-78.0) 36.9 (1-107) 0.62 DBLa1.5/6/8 types 10.8 (5.21-26.6) n=55 11.5 (2.75-22.9) 0.70 DBLa2/1.1/2/4/7 types 43.5 (23.6-69.8) n=55 49.1 (28.4-70.2) 0.42 a Median transcript levels were compared using Mann-Whitney U test Additional file 1: Figure S1. In siico characterization of primers used in the present study
12916_2017_945_MOESM1_ESM.docx